Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial

Sonya Elizabeth Craig,1 Malcolm Kohler,2 Debby Nicoll,1 Daniel J Bratton,3 Andrew Nunn,3 Robert Davies,1 John Stradling1,4

ABSTRACT
Background Continuous positive airway pressure (CPAP) for symptomatic obstructive sleep apnoea (OSA) improves sleepiness and reduces vascular risk, but such treatment for the more prevalent, minimally symptomatic disease is contentious.

Methods This multicentre, randomised controlled, parallel, hospital-based trial across the UK and Canada, recruited 391 patients with confirmed OSA (oxygen desaturation index > 7.5%/h) but insufficient symptoms to warrant CPAP therapy. Patients were randomised to 6 months of auto-adjusting CPAP therapy, or standard care. Coprimary endpoints were change in Epworth Sleepiness Score (ESS) and predicted 5-year mortality using a cardiovascular risk score (components: age, sex, height, systolic blood pressure, smoking, diabetes, cholesterol, creatinine, left ventricular hypertrophy, previous myocardial infarction or stroke). Secondary endpoints included some of the individual components of the vascular risk score, objectively measured sleepiness and self-assessed health status.

Results Of 391 patients randomised, 14 withdrew, 347 attended for their follow-up visit at 6 months within the predefined time window, of which 341 had complete ESS data (baseline mean 8.0, SD 4.3) and 310 had complete risk score data. 22% of patients in the CPAP group reported stopping treatment and overall median CPAP use was 2.39 h per night. CPAP significantly improved subjective daytime sleepiness (adjusted treatment effect on ESS = −2.0 (95% CI −2.6 to −1.4), p < 0.0001), objectively measured sleepiness and self-assessed health status. CPAP did not improve the 5-year calculated vascular risk or any of its components.

Conclusions In patients with minimally symptomatic OSA, CPAP can reduce subjective and objective daytime sleepiness, and improve self-assessed health status, but does not appear to improve calculated vascular risk.

INTRODUCTION
Obstructive sleep apnoea (OSA) leads to recurrent hypoxic episodes, repeated arousals, surges in blood pressure (BP) and, in some patients, excessive daytime sleepiness and raised diurnal BE. Approximately 20–30% of the middle-aged population has some degree of OSA, most with few or no symptoms.1 2 Severity of sleepiness from OSA correlates poorly with sleep study severity of OSA.3 This is likely due to inter-individual variation in the degree of brain arousal from apnoeas,4 the effect these arousals have on daytime function2 and an individual’s lifestyle. The UK National Institute for Health and Clinical Excellence (NICE) concluded that only two papers, with conflicting results, looked at the benefit of continuous positive airway pressure (CPAP) at low levels of OSA symptom severity.5 6 Thus one aim of the current study was to identify any symptomatic benefit from CPAP in sleep clinic patients with apparently minimal symptoms.

During each apnoea there are often recurrent hypoxic dips and surges in BP.7 These events may provoke sustained hypertension and several other potentially adverse cardiovascular consequences.8–14 While the acute effects of OSA on BP are abolished by CPAP9 any beneficial effects on sustained hypertension appear to be limited mainly to the more severe and symptomatic patients, with little benefit observed in non-sleepy patients in short-term randomised trials.6 8 Thus the second aim of this study was to assess the effect of 6 months of CPAP therapy on several potentially adverse vascular consequences, combined in an established calculated vascular risk algorithm in minimally symptomatic patients with OSA.

METHODS
Study design
The Multicentre Obstructive Sleep Apnoea Interventional Cardiovascular trial (MOSAIC) was a randomised, parallel, 6-month controlled trial that was conducted between May 2006 and February 2010. There were 10 recruiting centres in the UK and Canada, with Oxford as the coordinating centre. All centres are designated sleep units with facilities for diagnosis, treatment and follow-up of patients with OSA, and have healthcare professionals specifically trained in CPAP set-up and usage. The trial was approved by the ethics committees of all the centres (REC No: 05/ Q1604/159) and registered (ISRCTN 34164388).

Patients
Patients referred to sleep clinics, usually due to snoring, witnessed apnoeas or daytime sleepiness,
were assessed for eligibility and a screening log was kept. All patients were diagnosed with OSA using overnight respiratory polygraphy as standard in the participating centres. Patients were eligible if they were aged between 45 and 75 years, had proven OSA on the diagnostic sleep study, with >7.5 per hour oxygen desaturations of >4% (oxygen desaturation index, ODI), but had insufficient daytime symptoms associated with OSA to warrant CPAP therapy. This decision followed a detailed discussion between physician and patient about the evidence for possible benefits of CPAP versus the potentially lifelong nightly usage of a physical therapy. Thus patients with Epworth Sleepiness Scores (ESS) above the conventional upper normal limit (9) were included, when this was not accompanied by patient concerns. In addition, to ensure technical uniformity of the ODI across centres, a second domiciliary, overnight, pulse-oximetry recording (Konica-Minolta Inc, Osaka, Japan) was performed in all patients at baseline and at 6 months. This was used as the trial ODI value, which could therefore be different from the entry ODI. All patients who gave informed consent did so in accordance with Good Clinical Practice standards.

Continuous positive airway pressure
Patients assigned to CPAP were instructed in the use of an auto-adjusting CPAP machine (Autoset S8, ResMed, Abingdon, UK). Induction was by trained staff who were not involved in outcome assessments or data analysis. Humidification and interface choices were made on an individual basis. All patients had one or more follow-up visits to download compliance data, check for residual apnoea/hypopnoeas and mask leakage, and to make any necessary adjustments. There were routine telephone calls at 2 and 4 months, and telephone advice and replacement parts if requested by the patient.

Standard care
The standard care (SC) group had an identical planned visit schedule to the CPAP group. Both groups were asked to continue on their normal medication and not given any specific advice regarding diet and exercise.

Outcomes
The joint primary outcomes at 6 months (defined time window 5–8 months) were change in ESS, and change in a composite vascular risk endpoint, the 5-year risk of a fatal cardiovascular event calculated using a cardiovascular risk score. Secondary outcomes at 6 months were change in objective sleepiness, self-assessed health status, BP, lipids, glucose metabolism, obesity measures, vascular events and sleep apnoea severity (ODI).

Assessments of sleepiness
Subjective sleepiness was determined using the ESS,17 which assesses the tendency to fall asleep during eight typical daytime scenarios. Objective sleepiness was assessed using one Oxford Sleep Resistance (OSLER) test administered at the same time of day (Stowood Scientific Instruments Oxford, UK), a sleep resistance challenge which tests the ability to stay awake for 40 min in a quiet, darkened room.18,19

Self-assessed health status
The Medical Outcome Study, the 36-item Short-Form health survey (SF-36),20 the Calgary Sleep Apnoea Quality-of-Life Index (SAQLI)21 and the two-part Euroqol (EQ-5D) questionnaires22 were administered by trial staff and are described in the online supplementary appendix.

BP measurements and blood tests are also given in the online supplementary appendix.

Cardiovascular risk score
To avoid the problem of multiple comparisons, a calculated vascular risk score was used as a composite endpoint, thus allowing the inclusion of relevant factors with their correct relative weightings (only some of which could potentially be affected by OSA or its treatment). The algorithm proposed by Pocock et al22 is similar to the Framingham risk score but estimates the probability of a fatal cardiovascular event within 5 years from 11 factors: age (at baseline), sex, height, systolic BP (median of a 7-day period), total cholesterol, creatinine, cigarette smoking (current smoker if smoked in the previous month), diabetes (either on treatment, previously diagnosed and in general practice records, or fasting glucose ≥7 mmol/litre and haemoglobin A1c (HbA1c) >6.5%), left ventricular hypertrophy (Sokolov-Lyon method on ECG), history of cerebrovascular incident and/or myocardial infarction (from general practice records and verified from hospital case records if equivocal). Although some of these factors clearly could not change during follow-up (thus representing a ‘fixed offset’), their inclusion is necessary to derive a valid single risk score with the correct weightings.

Sample size calculation, randomisation data and statistical methods are given in the online supplementary appendix.

RESULTS
Flow diagram of trial allocation, implementation of intervention and baseline data
Figure 1 shows the trial profile. The trial was stopped nine patients short of the target of 400 because the number not attending for follow-up (4%) was lower than predicted (10%). Baseline data by group assignment are shown in table 1, and the baseline distribution of ESS scores by group assignment is shown in the online supplementary appendix (figure a).

Primary outcomes
Table 2 shows a summary of the adjusted treatment effects for the primary outcomes, including the results of the imputation and sensitivity analyses (further described in the online supplementary appendix). CPAP improved subjective sleepiness by a two-point reduction in the ESS scale compared with the SC group (95% CI −2.6 to −1.4; p<0.0001). There was a small, clinically insignificant, absolute increase of 0.1% in the 5-year risk of a fatal vascular event in the CPAP arm, relative to SC (95% CI 0.0% to +0.2%; p=0.070). The analyses of the components of the risk score in patients included in the primary risk score analysis are shown in table 3.

Secondary outcomes
Objective sleepiness
The proportion of patients falling asleep during the 40 min OSLER test was similar in the two groups at baseline (59% and 35% in the SC and CPAP group, respectively). At 6 months, the odds of falling asleep during the OSLER test were 44% lower in the CPAP treatment group compared with SC (95% CI −1.0 to −68%), p=0.045 (logistic regression). A ‘time to event’ (falling asleep) Kaplan–Meier plot of these data is shown in figure 2.

Indices of self-assessed health status
Most components of the SF-36 (except bodily pain, mental health and role physical) showed evidence of improvement following CPAP (tables 4 and 5, figure 3). The largest treatment effect was in energy/vitality, +6.6 (95% CI +3.1 to +10.1),
The mental component score improved by 2.6 points (95% CI +0.9 to +4.2), \( p=0.003 \). The SAQLI also showed a statistically significant improvement, but the small improvement in the Euroqol was not statistically significant (see online supplementary appendix tables a and b).

Other metabolic and vascular outcomes

Forty-three (22%) of the 195 patients randomised to CPAP reported stopping treatment during follow-up (see online supplementary appendix, tables c and d). Of the 172 patients on CPAP who attended their 6-month visit ‘on time’ (predetermined time window 5–8 months), 150 (87%) had compliance data at 6 months. Median CPAP usage was 2.39 h/night (IQR 0.36 to 4.59), with all patients in non-users with missing data at 6 months. Median CPAP usage was 2.39 h/night (IQR 0.36 to 4.59), with all patients in non-users with missing data at 6 months.

Following the end of the 6-month trial, 71% of patients randomised to CPAP expressed a wish to continue CPAP.

Effect of CPAP usage on outcomes

Figure 4A shows the effect of <4 h/night and ≥4 h/night of CPAP usage on change in ESS compared with SC. There was a statistically significant improvement in both groups, but the small improvement in the Euroqol was not statistically significant (see online supplementary appendix tables a and b).

Association of age, sex, ODI and hypertensive status with outcomes

The effect of CPAP therapy on ESS was largely independent of baseline ODI, age or sex (figure 5). There was some evidence of a small increase in ESS in patients with baseline ODI scores in the two quartiles above the median, but this was not statistically significant.

The effect of CPAP therapy on 5-year vascular risk was independent of baseline ODI, age, sex and hypertensive status (figure 5). The effect of CPAP therapy on systolic BP and HbA1c is detailed in the online supplementary appendix (figure 6). The effect of CPAP therapy on ODI is also shown in the online supplementary appendix (table c and d).

DISCUSSION

This study has shown that in minimally symptomatic patients with OSA, 6 months of CPAP therapy improves daytime sleepiness and self-assessed health status outcomes are detailed in the online supplementary appendix (figures a, b and c).

Figure 1: Flow diagram showing the trial allocation. BP, blood pressure; CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Score.
**Table 1** Baseline characteristics and minimisation variables in all MOSAIC patients

<table>
<thead>
<tr>
<th>Standard care (N=196)</th>
<th>CPAP (N=195)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epworth Sleepiness Score</td>
<td>8.0 (4.2)</td>
</tr>
<tr>
<td>Vascular risk score</td>
<td>35.7 (7.6)</td>
</tr>
<tr>
<td>Vascular risk score components</td>
<td></td>
</tr>
<tr>
<td>Sex (men)</td>
<td>152 (77.6%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.6 (7.5)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174.8 (8.8)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.2 (1.2)</td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>129.6 (13.6)</td>
</tr>
<tr>
<td>Creatinine (μmol/litre)</td>
<td>95.5 (18.8)</td>
</tr>
<tr>
<td>Left ventricular hypertrophy</td>
<td>3 (1.6%)</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>14 (7.1%)</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td>Diabetic</td>
<td>40 (20.4%)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>28 (14.3%)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>97 (49.5%)</td>
</tr>
<tr>
<td>Hypertensive</td>
<td>149 (76.0%)</td>
</tr>
<tr>
<td>Oxygen desaturation index (&gt;4% dips/h)</td>
<td>9.4 (5.2, 15.0)</td>
</tr>
<tr>
<td>Resting O2 saturation (%)</td>
<td>96.0 (1.4)</td>
</tr>
<tr>
<td>OSLER (min)</td>
<td>40.0 (25.8, 40.0)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>109.4 (12.9)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>32.5 (5.6)</td>
</tr>
<tr>
<td>Neck circumference (cm)</td>
<td>43.0 (4.0)</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>81.3 (7.7)</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD), median (25th, 75th percentiles) or number of patients (%).

**Table 2** Primary outcome results. Adjusted treatment effects (CPAP change minus standard care change) for ESS, and percentage risk of fatal cardiovascular event within 5 years

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Standard care (N=196)</th>
<th>CPAP (N=195)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESS 171/170</td>
<td>−2.0 (−2.6 to −1.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Primary analysis</td>
<td>156/154</td>
<td>+0.1 (0.0 to +0.2)</td>
</tr>
<tr>
<td>Sensitivity analysis</td>
<td>156/154</td>
<td>+0.1 (0.0 to +0.1)</td>
</tr>
<tr>
<td>Imputation analysis</td>
<td>175/172</td>
<td>+0.1 (0.0 to +0.2)</td>
</tr>
</tbody>
</table>

CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Score.

**Table 3** Baseline and follow-up means (SD) and adjusted treatment effects for the components of the vascular risk score

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Standard care, N=156</th>
<th>CPAP therapy, N=154</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic BP (mmHg)</td>
<td>130.1 (13.0)</td>
<td>129.8 (12.0)</td>
</tr>
<tr>
<td>Cholesterol (mmol/litre)</td>
<td>5.2 (1.1)</td>
<td>5.1 (1.2)</td>
</tr>
<tr>
<td>Creatinine (μmol/litre)</td>
<td>96.3 (19.2)</td>
<td>94.8 (19.9)</td>
</tr>
<tr>
<td>Current smoker (%)</td>
<td>22 (14.1)</td>
<td>19 (12.2)</td>
</tr>
<tr>
<td>Diabetic (%)</td>
<td>40 (20.4)</td>
<td>23 (11.8)</td>
</tr>
<tr>
<td>Myocardial infarction (%)</td>
<td>9 (5.8)</td>
<td>9 (5.8)</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>1 (0.6)</td>
<td>1 (0.6)</td>
</tr>
</tbody>
</table>

BP, blood pressure; CPAP, continuous positive airway pressure.

Sleep disordered breathing

The individuals in this study were less sleepy than in the majority of previous randomised controlled studies on CPAP. In two of our previous comparable trials the mean baseline ESS of 16, and the median baseline baseline ESS of 21 min, compares to about 8 and 40 min, respectively. The ESS improvement was seen across almost the whole spectrum of baseline ESS severity. Compared with SC, the number needed to treat for at least a two-point ESS improvement is about four (online supplementary appendix, table e). The fall in ESS of two points, relative to control, compares to a fall of about five points observed in one of our previous studies mentioned above. Because the ESS scale is an ordinal, rather than a linear, measure of sleepiness, it is difficult to compare changes at different points across the spectrum. However, in the NICE economic model, a drop of 2.5 in ESS in patients treated with CPAP incurred a cost of £9351 and was considered economically viable. This drop of two of ESS in would be expected in theory to improve work productivity by about 2% and reduce sleep-related road accident rates by about 9%, further adding to the cost efficacy of treatment.

This effect of CPAP on sleepiness was also observed almost equally across the whole ODI spectrum, confirming previous findings that the correlation between symptoms and apnoea-hypopnoea index (AHI), or ODI, is very poor. Nearly a quarter of patients started on CPAP in the current study admitted stopping therapy as they did not perceive benefits to outweigh inconvenience. However, 71% stated at the 6-month appointment that they wished to continue CPAP long term. This is similar to long-term CPAP take-up rates for patients with moderate OSA in many centres, including our own. From the baseline data we collected, there were no clear ways to predict in advance which individuals will benefit from treatment (figure 5).

We have also shown that self-assessed health status, as measured by SF-36 and SAQLI, improves with CPAP in patients with minimally symptomatic OSA. A previous randomised controlled trial of self-assessed health status in severely sleepy subjects with OSA showed treatment effects of 0.9 in the SAQLI and 14.5 in the Energy/Vitality component of SF-36, compared with the current trial of 0.6 and 6.6, respectively. This suggests that CPAP therapy in patients with minimally symptomatic OSA produces an improvement in self-assessed health status of 45–70% of that seen in severely sleepy patients.

Despite the clear symptomatic response to CPAP there was, if anything, weak evidence that vascular risk slightly worsened.
compared with SC, although the effect was clinically insignificant. This unimportant adverse effect was largely explained by small statistically non-significant differential changes in both smoking status and BP (and its medication) over the 6 months (table 2). Change in vascular risk did not seem to be related to initial OSA severity, or CPAP compliance, implying that we probably did not miss an effect, simply because overall compliance with CPAP was low. However, in the subgroup of patients with higher baseline ESS values (>11), there was a trend towards an improvement in vascular risk with CPAP (figure 5). Similarly systolic and diastolic BP, and cholesterol did fall in the CPAP arm relative to the SC arm in patients with higher ESS (>11), although these interactions were not statistically significant (online supplementary appendix, figures d–f). The drop in cholesterol of 0.30 mmol/litre in our most sleepy patients was similar to the findings of a previous study showing a fall in cholesterol of 0.28 mmol/litre in a more severely affected and sleepy population (mean ESS 16) treated for 1 month with CPAP.⁵¹ This suggests that patients with greater sleepiness benefit more than non-sleepy patients and supports previous findings.⁷ ⁸ ⁲⁵ A randomised controlled 12-month study by Barbe et al³² in a hypertensive non-sleepy population showed a small reduction in systolic and diastolic BP (1.9 and 2.2 mm Hg, p=0.07 and p=0.0008, respectively), but a larger effect (3.7 and 3.5 mm Hg, p=0.007 and p=0.0001, respectively) in patients with the highest CPAP compliance (>5.6 h/night) who also had the largest improvement in sleepiness. More recently, the same group³³ studied non-sleepy patients without prior cardiovascular events (some with hypertension) over a median of 4 years. Although there was no significant overall reduction in new events (predominantly new onset hypertension) in the CPAP group, the subgroup of patients prepared to use CPAP for >4 h/night did experience a reduction in vascular events. Interestingly, in both these trials the baseline AHI of the study population was higher (mean 45 and 39) than the ODI in our study (median 10), and thus these patients probably had worse OSA.

As no sham CPAP was used in our control group, our results might merely be due to a placebo effect of CPAP, observed in previous short trials.²⁴ ²⁵ However, as this was a 6-month trial, the placebo effect is likely to have diminished with time. In addition, previous studies employing sham CPAP did not generate placebo effects with the OSLER test,²⁴ yet we have demonstrated a significant treatment effect on this objective measure of sleepiness.

We adopted a clinical approach to setting up CPAP therapy, without overnight CPAP titration, which has become standard in many UK and European based sleep centres.³⁴ We obtained relatively low CPAP compliance, probably representing the likely usage when such non-sleepy patients are offered CPAP, which may have lessened the chance of demonstrating an effect on vascular risk, although there was no benefit in the sizeable subgroup of higher compliers. Similar to the current trial, CPAP compliance has been reported to be relatively low (2.9 h/night) in a study using overnight CPAP titration to establish an optimal pressure to abolish breathing irregularities in patients with mild OSA.⁵⁵ However, the Spanish group has managed to achieve higher compliance levels in their trials on non-sleepy patients (defined as ESS<10).³² ³³

---

**Table 4 SF-36 questionnaire**

<table>
<thead>
<tr>
<th>Energy/vitality</th>
<th>Standard care, N=168</th>
<th>CPAP, N=171</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline mean score (SD)</td>
<td>49.7 (23.7)</td>
<td>49.8 (22.4)</td>
</tr>
<tr>
<td>6-month mean score (SD)</td>
<td>53.9 (22.5)</td>
<td>60.6 (20.9)</td>
</tr>
<tr>
<td>Mean change (SE)</td>
<td>+4.2 (1.4)</td>
<td>+10.8 (1.3)</td>
</tr>
<tr>
<td>Adjusted treatment effect (95% CI), p value</td>
<td>+6.6 (+3.1 to +10.1), p&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Mean baseline and 6-month energy/vitality scores with adjusted treatment effect. An increase in the energy and vitality subscore indicates an improvement in health status. CPAP, continuous positive airway pressure; SF-36, 36-item Short-Form health survey.

---

**Table 5 SF-36 questionnaire**

<table>
<thead>
<tr>
<th>Mental component score</th>
<th>Standard care, N=158</th>
<th>CPAP, N=165</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline mean score (SD)</td>
<td>46.6 (11.3)</td>
<td>48.2 (10.4)</td>
</tr>
<tr>
<td>6-month mean score (SD)</td>
<td>48.5 (11.0)</td>
<td>52.0 (9.8)</td>
</tr>
<tr>
<td>Mean change (SE)</td>
<td>+1.9 (0.7)</td>
<td>+3.8 (0.6)</td>
</tr>
<tr>
<td>Adjusted treatment effect</td>
<td>+2.6 (+0.9 to +4.2), (95% CI), p value</td>
<td>p&lt;0.003</td>
</tr>
</tbody>
</table>

Mean baseline and 6-month mental component scores with adjusted treatment effect. An increase in mental component score indicates an improvement in health status. CPAP, continuous positive airway pressure.
It may be that the markers of cardiovascular risk included in the risk score are either too insensitive or unlikely to change in a 6-month period, and other markers such as endothelial function, sympathetic activity levels or circulating inflammatory markers may more sensitively reflect any risk reduction. However, short trials of 1-month duration in more severely affected patients have shown clear reductions in BP

Figure 4  Forest plots showing the adjusted treatment effects by continuous positive airway pressure (CPAP) compliance (<4 h/night and ≥4 h/night), with tests for interactions, on (A) Epworth Sleepiness Score (ESS) and (B) vascular risk (%).

Figure 5  Forest plots showing the adjusted treatment effects, with tests for interaction, on Epworth Sleepiness Score (ESS) (left panel, by sex and quartiles of age, baseline oxygen desaturation index (ODI) and baseline ESS), and on vascular risk (%) (right panel, by baseline hypertensive status and quartiles of age, baseline ODI, baseline ESS).
In conclusion, our findings show that even when there is little enthusiasm for CPAP by patient and physician, because of an apparent paucity of symptoms, nearly half of patients on CPAP experienced at least a two-point improvement in ESS. This positive treatment effect extends further down the spectrum of OSA symptom severity than was previously thought, but it is difficult to predict, at an individual level, which patients will benefit. However, this positive treatment effect on symptoms was not accompanied by a reduction in calculated vascular risk or BP. Thus CPAP should be offered to patients with OSA, despite minimal daytime symptoms, on a trial basis, but with the expectation that some will decide that the benefits do not justify the inconvenience and thus will return their equipment. Because this study was carried out in a general sleep clinic setting, it is therefore only applicable to mainstream sleep practice; the sleepiness and self-assessed health status benefits should not be extrapolated to subjects with undiagnosed OSA in the general population who have not had cause to present to a sleep clinic.

Contributors The authors fulfilled the criteria for authorship, had full access to all data in the study, and had final responsibility for the decision to submit for publication.

Funding The British Heart Foundation—unrestricted project grant, Oxford Health Services Research Committee paid for research salaries. ResMed UK made an unrestricted charitable donation to support research work in the Oxford Sleep Unit in 1998 and 2006, and supplied the CPAP machines for this trial. We would like to acknowledge the support of the NIHR Biomedical Research Centre Oxford.

Competing interest None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Downloaded from thorax.bmj.com on March 12, 2012 by guest. Protected by copyright.
Correction


The acknowledgement section for this article should read:

Principal investigators Dr Justin Pepperell, Dr Chris Davies, Prof. John Fleetham, Dr Mark Elliot, Dr Renata Riha, Dr Andrew Cummin, Dr Lee Dowson, Dr John White, Dr Anita Simmonds, Prof. Mary Morrell

Trial Steering Committee members Dr Ian Smith

Data monitoring committee Prof. Tim Peto, Prof. John Gibson

Advisors Prof. Peter Rothwell, Prof. Rory Collins

Research staff Barbara Winter, Rebecca Mason, Massimilliano Siccoli, Jacqui Webb, Suber Valmiki, Elizabeth Thorne, Nurit Fox, Margaret Chapman, Marjorie Vennelle, Craig Armstrong, Louise Spragg, Ramesh Ghiassi, Gillian Twigg, Neil Ward, Jayne Pateraki

Trial management Emma Hedley, Nicky Crosthwaite, Claire Manners, Magda Laskawiec

Data management Thomas Penning, Anna Bara, Peter Stradling, Phillippa Davies, Jenny Stradling, Adam Smith, Alice Roberts

We would like to acknowledge the support of the NIHR Biomedical Research Centre, Oxford, the British Heart Foundation, London, the Oxfordshire Health Services Research Committee, Oxford and Resmed, Abingdon.

Thorax 2013;68:96. doi:10.1136/thoraxjnl-2012-202178cor1